Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Alkem Laboratories
Join Channel
Consolidated Standalone

Alkem Laboratories

₹5668.5 24.9 | 0.4%

Market Cap ₹67775 Cr.

Stock P/E 30.6

P/B 5.4

Current Price ₹5668.5

Book Value ₹ 1055.2

Face Value 2

52W High ₹5783.3

Dividend Yield 0.79%

52W Low ₹ 4498.9

Edit Ratio

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Limited is a pharmaceutical agency. The Company is engaged inside the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates via 2 segments: pharmaceutical and investing. The Company produces generics,generic drugs, APIs and neutraceuticals, which it markets in India and about 50 international locations across the world. The Company offers numerous products, which include CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, amongst others. The Company has approximately 16 production facilities, of which 14 manufacturing facilities are at geographically different places in India and within the United States.

Read More..

Alkem Laboratories Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Alkem Laboratories Quarterly Results

#(Fig in Cr.) Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 2903 2968 3440 3324 2936 3032 3415 3374 3144 3371
Other Income 69 66 63 94 88 120 134 93 146 136
Total Income 2971 3034 3503 3418 3024 3152 3549 3467 3290 3508
Total Expenditure 2549 2579 2693 2616 2534 2423 2662 2615 2752 2632
Operating Profit 422 455 810 801 490 729 887 852 537 876
Interest 29 30 30 25 27 29 28 36 28 30
Depreciation 78 72 74 70 83 80 79 85 112 88
Exceptional Income / Expenses -103 0 -58 -51 -13 0 0 0 0 13
Profit Before Tax 212 353 648 655 367 619 780 731 396 771
Provision for Tax 144 65 33 51 63 69 78 90 73 103
Profit After Tax 68 288 615 604 304 550 702 641 323 668
Adjustments 3 -1 6 -9 -11 -5 -13 -15 -17 -4
Profit After Adjustments 71 287 621 595 294 545 689 626 306 664
Adjusted Earnings Per Share 5.9 24 51.9 49.8 24.6 45.6 57.6 52.3 25.6 55.6

Alkem Laboratories Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 3743 4925 5688 6392 7357 8344 8865 10634 11599 12668 12965 13304
Other Income 181 240 112 115 88 104 233 163 216 311 494 509
Total Income 3924 5165 5800 6507 7445 8449 9098 10797 11815 12978 13458 13814
Total Expenditure 3322 4072 4689 5383 6242 6871 6923 8581 9990 10422 10452 10661
Operating Profit 603 1093 1111 1124 1202 1578 2176 2216 1826 2556 3006 3152
Interest 81 71 45 55 55 65 59 52 107 112 122 122
Depreciation 71 93 101 143 193 253 275 304 310 299 357 364
Exceptional Income / Expenses 0 0 0 0 0 0 0 -15 -103 -121 0 13
Profit Before Tax 451 928 965 926 955 1260 1842 1844 1305 2023 2527 2678
Provision for Tax 59 176 60 288 181 110 224 164 298 212 311 344
Profit After Tax 392 752 905 638 774 1149 1618 1680 1007 1811 2216 2334
Adjustments 0 -11 -13 -7 -13 -22 -33 -35 -23 -16 -51 -49
Profit After Adjustments 392 742 892 631 761 1127 1585 1646 984 1796 2165 2285
Adjusted Earnings Per Share 32.8 62 74.6 52.8 63.6 94.3 132.6 137.7 82.3 150.2 181.1 191.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 2% 7% 9% 13%
Operating Profit CAGR 18% 11% 14% 17%
PAT CAGR 22% 10% 14% 19%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -1% 21% 15% NA%
ROE Average 20% 17% 19% 18%
ROCE Average 22% 18% 19% 19%

Alkem Laboratories Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 2999 3692 4468 4864 5439 6161 7377 8638 9045 10312 11985
Minority's Interest 86 95 115 122 133 148 181 209 390 402 449
Borrowings 33 123 182 131 231 74 28 9 0 40 311
Other Non-Current Liabilities 167 -430 -582 -489 -520 -614 -779 -902 -688 -689 -757
Total Current Liabilities 2006 1538 1690 2383 2218 3245 3604 4805 3707 3995 3959
Total Liabilities 5291 5018 5872 7010 7501 9013 10411 12760 12454 14060 15953
Fixed Assets 1374 1450 1797 2284 2530 2908 2793 2902 2683 2873 2852
Other Non-Current Assets 1579 800 1158 713 754 599 690 1423 1042 776 2155
Total Current Assets 2338 2769 2915 4013 4204 5488 6923 8434 8606 10412 10811
Total Assets 5291 5018 5872 7010 7501 9013 10411 12760 12454 14060 15953

Alkem Laboratories Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 101 124 127 167 167 249 176 174 232 274 66
Cash Flow from Operating Activities 325 726 471 266 780 585 1265 1111 1683 1948 1913
Cash Flow from Investing Activities -237 202 -286 -357 -316 -741 -999 -1435 113 -1009 -1299
Cash Flow from Financing Activities -52 -927 -138 85 -379 79 -272 380 -1761 -1145 -811
Net Cash Inflow / Outflow 37 1 47 -7 84 -77 -5 55 35 -205 -197
Closing Cash & Cash Equivalent 140 127 167 167 249 176 174 232 274 66 -120

Alkem Laboratories Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 32.76 62.03 74.62 52.78 63.61 94.28 132.58 137.65 82.32 150.21 181.14
CEPS(Rs) 38.69 70.73 84.14 65.37 80.87 117.28 158.29 165.98 110.18 176.56 215.24
DPS(Rs) 4 12.7 15 13 16 25 30 34 50 40 45
Book NAV/Share(Rs) 250.86 308.82 373.67 406.76 454.86 515.21 616.95 722.48 756.56 860.94 999.47
Core EBITDA Margin(%) 10.93 16.9 17.07 11.76 10.41 11.89 14.82 13.44 8.97 11.58 13.01
EBIT Margin(%) 13.78 19.8 17.25 11.43 9.42 10.69 14.5 12.42 7.87 11.02 13.72
Pre Tax Margin(%) 11.68 18.39 16.48 10.79 8.91 10.16 14.05 12.07 7.27 10.44 13.09
PAT Margin (%) 10.15 14.9 15.46 7.44 7.22 9.27 12.34 11 5.61 9.35 11.48
Cash Profit Margin (%) 11.98 16.75 17.19 9.1 9.03 11.31 14.43 12.99 7.34 10.89 13.33
ROA(%) 8.16 14.59 16.61 9.91 10.66 13.92 16.66 14.5 7.99 13.66 14.77
ROE(%) 14.03 22.48 22.18 13.69 15.02 19.82 23.91 20.99 11.39 18.74 19.93
ROCE(%) 13.27 23.1 21.31 17.86 16.49 18.71 22.56 18.69 13.09 19.52 21.56
Receivable days 42.27 39.57 39.95 38.15 39.69 42.66 45.33 41.72 40.86 41.28 44.62
Inventory Days 66.41 61.23 65.96 56.31 50.14 48.86 57.51 63.54 57.1 49.6 52.79
Payable days 96.89 117.1 133.45 156.37 135.69 118.18 118.18 114.79 97.4 122.87 158.86
PER(x) 0 22.03 29.58 37.46 27.54 24.7 20.91 26.28 41.27 32.89 26.94
Price/Book(x) 0 4.42 5.91 4.86 3.85 4.52 4.49 5.01 4.49 5.74 4.88
Dividend Yield(%) 0 0.93 0.68 0.66 0.91 1.07 1.08 0.94 1.47 0.81 0.92
EV/Net Sales(x) 0.14 3.29 4.68 3.76 2.88 3.4 3.71 4.07 3.39 4.63 4.46
EV/Core EBITDA(x) 0.89 14.83 23.98 21.4 17.65 17.98 15.1 19.52 21.53 22.96 19.24
Net Sales Growth(%) 19.75 31.56 15.49 12.38 15.1 13.42 6.24 19.96 9.08 9.21 2.34
EBIT Growth(%) 1.7 87.93 1.01 -2.82 2.85 31.27 43.49 -0.23 -25.55 51.23 24.03
PAT Growth(%) -10.05 92.1 20.27 -29.43 21.18 48.56 40.76 3.87 -40.08 79.92 22.33
EPS Growth(%) -10.01 89.38 20.29 -29.27 20.54 48.2 40.63 3.82 -40.19 82.47 20.59
Debt/Equity(x) 0.44 0.18 0.15 0.21 0.17 0.26 0.23 0.3 0.14 0.12 0.09
Current Ratio(x) 1.17 1.8 1.73 1.68 1.9 1.69 1.92 1.76 2.32 2.61 2.73
Quick Ratio(x) 0.77 1.21 1.01 1.08 1.22 1.13 1.28 1.13 1.62 1.94 1.99
Interest Cover(x) 6.56 14.03 22.36 17.74 18.48 20.36 32.26 36.22 13.15 19 21.76
Total Debt/Mcap(x) 0 0.04 0.02 0.04 0.05 0.06 0.05 0.06 0.03 0.02 0.02

Alkem Laboratories Shareholding Pattern

# Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Promoter 57.16 56.74 56.74 56.74 56.38 55.66 55.66 55.13 53.04 51.2
FII 5.64 6.03 8.49 9.11 8.69 9.02 10.15 9.41 9.11 9.48
DII 16.34 17.64 15.91 15.63 18.57 19.21 18.01 19.42 21.8 21.93
Public 20.86 19.59 18.86 18.52 16.36 16.1 16.18 16.05 16.05 17.4
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company is almost debt free.

Cons

  • Debtor days have increased from 122.87 to 158.86days.
  • Stock is trading at 5.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alkem Laboratories News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!